AirNexis Therapeutics
AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions.
$200M Series A ·
Led by Frazier Life Sciences · Source: fundraisingfox.com
Funding history ↓Signals
Website registeredOct 28, 2024 (2 years old)
Funding rounds
- Series A · $200M
FFrazier Life Sciences (lead),
EEnavate Sciences,
GGoldman Sachs Alternatives,
LLongitude Capital,
OOrbiMed,
SSR One
Source: fundraisingfox.com - Website created
Investors
Companies like AirNexis Therapeutics
VVaderis Therapeutics$152M Series B+ · Aug 2026
SStorm Therapeutics$56M Series B+ · Apr 2026
CComplement TherapeuticsSeries A · Apr 2023
TTune Therapeutics$175M Series B+ · Jan 2025
CCelea Therapeutics$180M Series A · Jul 2026
AAltay Therapeutics
Other companies backed by Frazier Life Sciences
RRQ Bio$115M Series A · Jun 2026
IImmutrin$86.45M Series A · Mar 2026
AAngitia Bio$130M Series B+ · Feb 2026
AAspen Neuroscience$115M Series B+ · Nov 2025
TTubulis$360M Series B+ · Oct 2025AAlpha-9 Oncology$175M Series B+ · Oct 2024
Frazier Life Sciences portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/airnexis-therapeutics (get a free API key).